ClinicalTrials.gg
Active, not recruitingNCT06834932Updated Nov 13, 2026

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia

A Phase 2/3 interventional study of Placebo and Rosuvastatin Dose 1 in Dyslipidaemia, sponsored by AstraZeneca. Active, not recruiting at 40 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by AstraZeneca · Phase 2/3, Interventional, and Treatment

Updated Nov 13, 2026Primary completion moved2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.

Enrollment
Largest of 11
432 · median 59
Started
2024
with 3 others
Phase 2/3
Only one
of the 11
Registered
6th of 11
by date
Lead sponsor
11 of 11
AstraZeneca

Among the 11 studies testing laroprovstat in Dyslipidemias, this one has the largest enrollment, is one of 4 that started in 2024, is the only one in phase 2/3, and was the 6th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About laroprovstat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing laroprovstat in Dyslipidemias as a file.
02

Study summary

This is a randomised, double-blind, placebo-controlled, multi-centre, sequential Phase II and Phase III study that will evaluate the efficacy, safety, and PK of AZD0780 administered orally for up to 52 weeks in participants with elevated LDL-C. The study consist of 2 separate parts (Part A and Part B) approximately 60 participants will be randomised in Part A. There will be 2 cohorts in Part B (approximately 220 participants in Cohort 1 and 100 participants in Cohort 2).

Read the detailed description

The planned study includes 2 parts. Part A will be the Phase II study and aims to evaluate the PK, PD, safety, and tolerability of AZD0780. Part B will be the Phase III study and aims to evaluate the reduction of LDL-C as well as the safety and tolerability after oral administration of AZD0780 on background lipid-lowing therapy including moderate to high-intensity statins.

For Part A, approximately 60 participants who meet the eligibility criteria will be randomised. Part A will comprise 4 periods totalling up to 80 days.

For Part B, approximately 220 participants who meet the eligibility criteria will be randomised in Cohort 1, and approximately 100 participants who meet the eligibility criteria will be randomised in Cohort 2.

Cohort 1: participants are on a stable dose of LLTs, including moderate to high-intensity statins for≥ 28 days before screening.

Cohort 2: participants could be with moderate-intensity or without statins therapy (not due to statin intolerance) in background LLTs or not on any LLTs .

03

Conditions studied

  • Dyslipidaemia

Browse trials for

Keywords

  • AZD0780
  • Dyslipidaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PART A

  1. Males, and females of non-, 18 to 55 years of age, at the time of signing the .
  2. Diagnosis of dyslipidaemia: and with fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L) and \< 190 mg/dL (4.9 mmol/L) at screening (Visit 1).
  3. Fasting triglycerides \< 400 mg/dL (\< 4.52 mmol/L) at screening (Visit 1).
  4. Not on any LLTs for ≥ 8 weeks prior to screening (Visit 1), except for a heart-healthy lifestyle.
  5. No planned LLTs using during study participation.
  6. ≥ 18 and ≤35 kg/m\^2 , weigh ≥50 kg and ≤120 kg.

PART B

  1. Males, and females, ≥ 18 years of age, at the time of signing the informed consent.
  2. Meets one of the ASCVD status/risk categories and has a corresponding fasted LDL-C value at screening (Visit 1) .

(1) Participants with clinical ASCVD, LDL-C ≥ 55 mg/dl (ultra-high risk) and ≥ 70 mg/dl (very high risk).

(2) Participants without clinical ASCVD, at moderate to high risk for ASCVD at 10 years, LDL-C ≥ 100 mg/dl. ASCVD risk equivalents [diabetes mellitus,LDL-C ≥ 4.9 mmol/L or TC ≥ 7.2 mmol/L, HeFH, CKD (stage 3-5)] are also eligible.

3. Fasting triglycerides \< 400 mg/dL (\< 4.52 mmol/L).

4. Background LLTs:

For Cohort 1: on a stable dose of LLTs including medications and supplements ≥ 28 days before screening (Visit 1). , that typically include moderate to high-intensity statins for ≥ 28 days before screening (LLTs include medications [eg, statins, ezetimibe, niacin] and supplements [eg, omega-3 fatty acids] that can affect cholesterol levels).

  1. Participants intolerant to moderate or high intensity statins per the 2023 Chinese Guideline may be included if treated with a low intensity statin.
  2. Participants not on statins must have documented intolerance to at least two statins (including one at the lowest standard dose) or be on chronic medication contraindicating statin use.

For Cohort 2: Meet one of the following before screening (Visit 1):

  1. On a stable dose of LLTs including moderate statins .
  2. On a stable dose of LLTs without any statins.
  3. Not received treatment with any LLTs.

Exclusion criteria

Exclusion Criteria:

PART A

  1. (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in-situ, or Stage 1 prostate carcinoma) within the last 10 years.
  2. Recipient of any major organ transplant, eg, lung, liver, heart, bone marrow, renal.
  3. Homozygous familial hypercholesterolaemia, Know diagnosis of HeFH, LDL apheresis or plasma apheresis within 12 months prior to screening (Visit 1).
  4. > 450 ms; high degree atrioventricular-block grade II-III and sinus node dysfunction with significant sinus pause untreated with pacemaker; and cardiac tachyarrhythmias.
  5. A LDL-C reduction that is \< 30% post rosuvastatin run-in period (Day -8).

PART B

  1. Acute ischaemic ASCVD event within 7 days prior to screening (Visit 1).
  2. Any uncontrolled or serious disease.
  3. \< 15 mL/min/1.73m2 using the CKD-EPI 2021 (age, sex) equation at screening (Visit 1).
  4. Uncontrolled type 2 diabetes mellitus, defined as ≥ 9.5% at screening (Visit 1).
  5. Heart failure with Class IV.
  6. Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma) within 5 years prior to screening (Visit 1).
  7. Severe concomitant non-CVD with risk of \< 2 years.
  8. Recipient of any major organ transplant, eg, lung, liver, heart, bone marrow, renal.
  9. Homozygous familial hypercholesterolaemia, LDL apheresis, or plasma apheresis within 12 months prior to screening or any other underlying known disease or condition that may interfere with interpretation of the clinical study results as judged by the Investigator.
  10. Uncontrolled hypertension defined as average sitting SBP > 160 mmHg or DBP > 110 mmHg at screening (Visit 1) or randomization despite antihypertensive therapy (based on the mean of the 3 consecutive readings).
  11. Any laboratory values with the following deviations at screening (Visit 1)

    1. Any positive result on screening for or .
    2. > 3 × .
    3. AST > 3 × ULN.
    4. TBL > 2 × ULN (except for participants with Gilberts syndrome, where TBL 3 × ULN is acceptable provided direct \< 1.5 × ULN)
    5. Creatine kinase > 5 × ULN
    6. Urine albumin-to-creatinine ratio ≥ 500 mg/g
  12. QTcF > 470 ms; high degree atrioventricular-block grade II-III and sinus node dysfunction with significant sinus pause untreated with pacemaker; and cardiac tachyarrhythmias.
  13. Current administration of PCSK9 inhibitor, siRNA or mAb (approved or ) at screening.
  14. Mipomersen or microsomal triglyceride transfer protein inhibitor (eg, lomitapide) use within 12 months prior to screening or planned ues during the study.
  15. Use of PCSK-9 inhibitors: evolocumab/alirocumab within 12 weeks, inclisiran within 18 months, tafolecimab, ebronucimab, ongericimab, and recaticimab within 3 to 6 months before screening or planned use during the study; or any other PCSK-9 inhibitor within 5 half-lives before screening or planned use during the study.
  16. Use of any lipid-lowing traditional Chinese medicine (expect Xuezhikang) within 8 weeks before screening.
  17. Use of gemfibrozil within one week before screening or planned use during the study.
  18. Receiving, or has received within 14 days of screening, medication with a black box warning for significant QT prolongation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
432 participants (actual)

Study arms

  • Experimental
    AZD0780 +Rosuvastatin Dose 1 (Part A)

    * Participants will receive Rosuvastatin Dose 1 QD for minimum 21 days (up to 28 days) * Then receive AZD0780 QD as add on for next 28 days (Part A)

    Drug: Rosuvastatin Dose 1 · Drug: AZD0780

  • Placebo comparator
    Placebo +Rosuvastatin Dose 1 (Part A)

    * Participants will receive Rosuvastatin Dose 1 QD for minimum 21 days (up to 28 days) * Then receive Placebo QD as add on for next 28 days (Part A)

    Drug: Placebo · Drug: Rosuvastatin Dose 1

  • Experimental
    AZD0780 +Rosuvastatin Dose 2 (Part A)

    * Participants will receive Rosuvastatin Dose 2 QD for minimum 21 days (up to 28 days) * Then receive AZD0780 QD as add on for next for 28 days (Part A)

    Drug: Rosuvastatin dose 2 · Drug: AZD0780

  • Placebo comparator
    Placebo + Rosuvastatin Dose 2 (Part A)

    * Participants will receive Rosuvastatin Dose 2 QD for minimum 21 days (up to 28 days) * Then receive Placebo QD as add on for 28 days (Part A)

    Drug: Placebo · Drug: Rosuvastatin dose 2

  • Experimental
    AZD0780 (Part B Cohort 1)

    • Participate will receive AZD0780 QD for 52 weeks (Part B Cohort 1)

    Drug: AZD0780

  • Placebo comparator
    Placebo (Part B Cohort 1)

    • Participate will receive Placebo QD for 52 weeks (Part B Cohort 1)

    Drug: Placebo

  • Experimental
    AZD0780+Rosuvastatin Dose 1 (Part B Cohort 2)

    * Participate receive Rosuvastatin Dose 1 for 28 days. * Then receive AZD0780 QD as add on for 12 weeks (Part B Cohort 2)

    Drug: Rosuvastatin Dose 1 · Drug: AZD0780

  • Placebo comparator
    Placebo+Rosuvastation Dose 1 (Part B Cohort 2)

    * Participate receive Rosuvastatin Dose 1 for 28 days. * Then receive Placebo QD as add on for 12 weeks (Part B Cohort 2)

    Drug: Placebo · Drug: Rosuvastatin Dose 1

Interventions

  • DrugPlacebo

    Administered orally as tablets

  • DrugRosuvastatin Dose 1

    Administered orally as tablets

  • DrugRosuvastatin dose 2

    Administered orally as tablets

  • Administered orally as tablets

06

What researchers measure

Primary outcomes

  1. AZD0780 Concentrations in plasma (PART A)

    To characterise the single dose and steady state PK of AZD0780 following oral administration of AZD0780 (PART A)

    Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)

  2. AZD0780 PK Parameter: AUC0-t (PART A, intensive PK subgroup).

    To characterise the single dose and steady state PK of AZD0780 following oral administration of AZD0780 (PART A)

    Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)

  3. AZD0780 PK parameter: Cmax (PART A, intensive PK subgroup)

    To characterise the single dose and steady state PK of AZD0780 following oral administration of AZD0780 (PART A)

    Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)

  4. AZD0780 PK parameter: AUCtau (PART A, intensive PK sub group)

    To characterise the single dose and steady state PK of AZD0780 following oral administration of AZD0780 (PART A)

    Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)

  5. Relative change in LDL-C from baseline to 12 weeks (PART B)

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks (PART B)

    Time frame: From baseline to 12 weeks (PART B)

Secondary outcomes

  1. Relative change from baseline of LDL-C at Week 4 (PART A)

    To evaluate the effect of treatment with AZD0780 versus placebo on LDL-C at Week 4 (PART A)

    Time frame: From baseline to Week 4 (PART A)

  2. Relative change in LDL-C from baseline to 12 weeks (PART B Cohort 2)

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks in Cohort 2 (PART B)

    Time frame: From baseline to 12 weeks (PART B Cohort 2)

  3. Relative change in LDL-C from baseline to 12 weeks (PART B)

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks in participants on background statin therapy at baseline (PART B)

    Time frame: From baseline to 12 weeks (PART B)

  4. Indicator for LDL-C < 70 mg/dL (< 1.8 mmol/L) at 12 weeks (PART B)

    To compare the effect of treatment with AZD0780 versus placebo on the probability of LDL-C \< 70 mg/dL at 12 weeks in participants with baseline LDL-C ≥ 70 mg/dL (PART B)

    Time frame: From baseline to 12 weeks (PART B)

  5. Indicator for LDL-C < 55 mg/dL (< 1.4 mmol/L) at 12 weeks (PART B)

    To compare the effect of treatment with AZD0780 versus placebo on the probability of LDL-C \< 55 mg/dL at 12 weeks (PART B)

    Time frame: From baseline to 12 weeks (PART B)

  6. Relative change in LDL-C from baseline to 28 weeks (PART B cohort 1)

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 28 weeks in Cohort 1 (PART B cohort 1)

    Time frame: From baseline to Week 28 (PART B cohort 1)

  7. Relative change in LDL-C from baseline to 52 weeks (PART B cohort 1)

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 52 weeks in Cohort 1 (PART B cohort 1)

    Time frame: From baseline to Week 52 (PART B cohort 1)

  8. Relative change in lipid panel from baseline to 12 weeks (PART B cohort 2)

    To compare the effect of treatment with AZD0780 versus placebo on lipid panel at 12 weeks (PART B cohort 2)

    Time frame: From baseline to Week 12 (PART B cohort 2)

Other outcomes

  1. Number of participants with adverse events (PART A)

    To assess the safety and tolerability of AZD0780 following oral administration of multiple doses (PART A)

    Time frame: From baseline up to Day 39 (PART A)

  2. Number of participants with adverse events (PART B)

    To assess the safety and tolerability of AZD0780 versus placebo (PART B)

    Time frame: Cohort 1: From baseline up to Day 375 (PART B) Cohort 2: From baseline up to Day 95 (PART B)

07

Study locations

40 sites
  • Research Site
    Baotou, 14010, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changchun, 130033, China
  • Research Site
    Changde, 415000, China
  • Research Site
    Changsha, 410015, China
  • Research Site
    Changzhou, 272100, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chongqing, 402260, China
  • Research Site
    Daqing, 163000, China
  • Research Site
    Deyang, 618000, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Guangzhou, 510220, China
  • Research Site
    Hengyang, 421001, China
  • Research Site
    Heze, 274099, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Luoyang, 471000, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Nanchong, 637900, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Pingxiang, 337055, China
  • Research Site
    Qiqihar, 161000, China
  • Research Site
    Sanya, 572000, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200120, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Siping, 136000, China
  • Research Site
    Taiyuan, 030024, China
  • Research Site
    Tianjin, 300457, China
  • Research Site
    Wuhan, 430010, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Xi'an, 710068, China
  • Research Site
    Xianyang, 750004, China
  • Research Site
    Yinchuan, 750004, China
  • Research Site
    Zigong, 643021, China
  • Research Site
    Hong Kong, 999077, Hong Kong
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2024 (actual). Primary completion is estimated for Feb 2027, 26 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2025 → Feb 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Feb 19, 2025
StartActual
Dec 6, 2024
Primary completionEst.
Feb 22, 2027was Jul 2025
CompletionEst.
Feb 22, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed
Show 2 removed
  • Research Site · Shanghai, China
  • Research Site · Shatin, Hong Kong
Nov 13, 2026
Primary completion
Jul 3, 2025→Feb 22, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    2 sites removed
    Show 2 removed
    • Research Site · Shanghai, China
    • Research Site · Shatin, Hong Kong
    Primary completion Jul 3, 2025→Feb 22, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06834932
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Dec 6, 2024
Primary completion
Feb 22, 2027 (estimated)
Completion
Feb 22, 2027 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion